hypoxia-inducible factor prolyl hydroxylase; Egl nine homolog; HIF-prolyl hydroxylase (EGLN)
Jump to navigation
Jump to search
Function
- oxygen-dependent proteasomal degradation of hypoxia inducible factor
Pharmacology
- HIF prolyl hydroxylase inhibitors stabilize HIF, which in turn stimulate endogenous erythropoietin production
More general terms
More specific terms
- Egl nine homolog 1; hypoxia-inducible factor prolyl hydroxylase 2; HIF-PH2; HIF-prolyl hydroxylase 2; HPH-2; prolyl hydroxylase domain-containing protein 2; PHD2; SM-20 (EGLN1, C1orf12, PNAS-118, PNAS-137)
- Egl nine homolog 2; estrogen-induced tag 6; hypoxia-inducible factor prolyl hydroxylase 1; HIF-PH1; HIF-prolyl hydroxylase 1; HPH-1; prolyl hydroxylase domain-containing protein 1; PHD1 (EGLN2, EIT6)
- Egl nine homolog 3; hypoxia-inducible factor prolyl hydroxylase 3; HIF-PH3; HIF-prolyl hydroxylase 3; HPH-3; prolyl hydroxylase domain-containing protein 3; PHD3 (EGLN3)
Additional terms
References
- ↑ UniProt http://www.uniprot.org/uniprot/Q96KS0-.html
- ↑ UniProt http://www.uniprot.org/uniprot/Q9GZT9.html
- ↑ UniProt http://www.uniprot.org/uniprot/Q9H765.html
- ↑ Chertow GM, Pergola PE, Farag YMK Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med 2021; 384:1589-1600. April 29 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33913637 https://www.nejm.org/doi/full/10.1056/NEJMoa2035938